argenx_logo_default.png
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 01:00 ET | argenx SE
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan’s Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG) ...
argenx_logo_default.png
argenx announces results of Annual General Meeting of Shareholders
May 11, 2021 05:00 ET | argenx SE
May 11, 2021Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
May 07, 2021 01:00 ET | argenx SE
May 7, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,...
argenx_logo_default.png
argenx Management to Present at Upcoming Virtual Investor Conferences
April 28, 2021 01:00 ET | argenx SE
April 28, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx announces Annual General Meeting of Shareholders on May 11, 2021
March 30, 2021 16:00 ET | argenx SE
March 30, 2021 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
March 04, 2021 01:00 ET | argenx SE
- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG) - Pre-approval access program opened...
argenx_logo_default.png
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
March 02, 2021 02:00 ET | argenx SE
Regulated Information/Inside Information argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis If approved, efgartigimod will be the...
argenx_logo_default.png
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
February 25, 2021 01:00 ET | argenx SE
February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx announces closing of global offering
February 05, 2021 16:01 ET | argenx SE
Regulated information February 5, 2021 Breda, the Netherlands / Ghent, Belgium — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx_logo_default.png
argenx announces full exercise of underwriters’ option to purchase additional ADSs
February 04, 2021 01:00 ET | argenx SE
Regulated information — Inside information February 4, 2021 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...